Form 4: BioXcel CEO Vimal Mehta Reports RSU Conversions

BioXcel Therapeutics CEO and President Vimal Mehta reported the conversion of Restricted Stock Units into common stock on December 14 and 15, 2025.

Summary

• Vimal Mehta, CEO and President of BioXcel Therapeutics, Inc. (BTAI), reported changes in beneficial ownership via a Form 4 filing.
• On December 14, 2025, 164 shares of common stock were acquired through the conversion of Restricted Stock Units (RSUs).
• On December 15, 2025, an additional 219 shares of common stock were acquired through the conversion of RSUs.
• Following these transactions, Mehta directly owns 20,876 shares of common stock.
• Mehta also indirectly owns 125 shares through a spouse and 480,343 shares through BioXcel LLC.
• The RSUs converted on December 14, 2025, were part of a grant of 2,609 RSUs on March 14, 2022, vesting as to 25% on the first anniversary and 6.25% each successive three-month period thereafter.
• The RSUs converted on December 15, 2025, were part of a grant of 3,500 RSUs on March 15, 2023, vesting as to 25% on the first anniversary and 6.25% each successive three-month period thereafter.

Sentiment

Score: 6

Explanation: The filing reports routine vesting and conversion of Restricted Stock Units by the CEO, leading to an increase in his direct beneficial ownership. This is generally viewed as a positive for aligning management and shareholder interests, though it's a pre-scheduled event rather than a discretionary purchase.

Positives

• Increased direct beneficial ownership by a key executive (CEO and President) through RSU conversions, which generally aligns management interests with shareholders.

Risks

• The reporting person disclaims beneficial ownership of the securities held by BioXcel LLC except to the extent of his pecuniary interest therein, which is a standard disclaimer for indirect holdings.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Indirect beneficial ownership of 125 shares of common stock by Vimal Mehta's spouse.
• Indirect beneficial ownership of 480,343 shares of common stock by BioXcel LLC, a subsidiary of BioXcel Holdings, Inc. Vimal Mehta is an executive officer and the sole member of the board of directors of BioXcel Holdings, Inc., and an executive officer and one of two managers on the board of managers of BioXcel LLC and BioXcel Holdings, Inc.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's interests with shareholders due to higher direct stock ownership.
• Employees: The RSU vesting structure incentivizes continuous employment of key executives.

Next Steps

• Continued vesting of remaining Restricted Stock Units granted on March 14, 2022, and March 15, 2023, subject to the reporting person's continuous employment with the Issuer through the relevant vesting dates.

Key Dates

Recommendation

This Form 4 reports routine, pre-scheduled vesting and conversion of Restricted Stock Units by the CEO. While it increases insider ownership, which is generally positive for aligning interests, it does not represent a discretionary purchase or sale that would signal a strong change in management's outlook on the company's immediate prospects. Therefore, it does not provide a basis for a change in investment recommendation.

Keywords

BioXcel Therapeutics, BTAI, Vimal Mehta, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Beneficial Ownership, CEO, President